Gabapentin Capsule
Product Images NDC 50090-6875

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-6875). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation Of Cockcroft And Gault (Gabapentin Fig1)

An illustration showing the formula for calculating creatinine clearance (CLCr). The formula includes variables for age in years, weight in kilograms, serum creatinine in mg/dl, and a factor of 0.85 applied for female patients.*

FDA Label Image

Fig-2 (Gabapentin Fig2)

A line graph showing mean pain score over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period, with Gabapentin showing a decrease in mean pain score over time compared to the placebo.*

FDA Label Image

Fig-3 (Gabapentin Fig3)

A line graph depicting mean pain scores over 7 weeks for placebo and two gabapentin dosage groups (1800 mg/day and 2400 mg/day). The chart shows a 3-week dose titration period followed by a 4-week fixed dose period, with pain scores decreasing more in gabapentin groups compared to placebo.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

Bar graph titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing comparisons between placebo (PBO) and Gabapentin (GBP) at different doses in two studies. Study 1 compares PBO (12%) and GBP 3600 mg (29%). Study 2 shows PBO (14%), GBP 1800 mg (32%), and GBP 2400 mg (34%). Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot showing percentage difference on the y-axis versus daily dose in mg on the x-axis. Data points are grouped by three studies labeled 'STUDY a,' 'STUDY b,' and 'STUDY c.' The daily doses displayed are 600, 900, 1200, and 1800 mg, with percentage differences ranging from around 2% to 22%. Each data point includes superscript letter annotations (a, b, c) indicating comparison groups within the studies.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure diagram of Gabapentin, showing a cyclohexane ring with attached amino (CH2NH2) and carboxymethyl (CH2CO2H) functional groups.*

FDA Label Image

Label Image (Lbl500906875)

Label for Gabapentin 100 mg oral capsules from A-S Medication Solutions. The label includes dosage strength and quantity of 90 capsules per package. Storage instructions specify keeping the product between 68 and 77 degrees Fahrenheit. The label also includes the product NDC 50090-6875-0 and a QR code for dosage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.